Keybanc Maintains Overweight on Health Catalyst, Lowers Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Keybanc analyst Scott Schoenhaus has maintained an Overweight rating on Health Catalyst (HCAT) but has lowered the price target from $12 to $10.
February 26, 2024 | 10:23 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Keybanc maintains an Overweight rating on Health Catalyst but lowers the price target from $12 to $10.
While the maintenance of an Overweight rating suggests continued confidence in Health Catalyst's fundamentals and growth potential, the reduction in price target could reflect adjustments in market conditions or expectations. This mixed signal might lead to short-term uncertainty among investors, potentially stabilizing the stock price as the market digests the news.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100